Clinical Trials Logo

Filter by:
NCT ID: NCT04670614 Completed - Clinical trials for Post-operative Surgical Pain

Regional Anesthesia (Supra-Orbital and Infra-Orbital Nerve Block) (SION) for Pain Management in Trans-sphenoidal Hypophysectomy

SION
Start date: January 15, 2017
Phase: N/A
Study type: Interventional

This is a prospective, randomized, blinded, sham controlled regional anesthetic (supra-orbital and infra-orbital nerve block) pain study to compare the systemic postoperative pain medication requirements in patients having Trans-sphenoidal Pituitary surgery. The patients will receive general anesthesia +/- regional anesthesia for trans-sphenoidal pituitary surgery and systemic pain medication during the intra-operative and postoperative (6hrs) period. The amount of systemic pain medication requirements will be compared between those patients receiving regional and general anesthesia versus general anesthesia alone.

NCT ID: NCT04670575 Completed - Cataract Clinical Trials

Vivity Outcomes in Patients With Early Stage Glaucoma

VIVA
Start date: January 1, 2021
Phase:
Study type: Observational

The goal of the study is to determine the visual outcomes in patients with mild, pre-perimetric glaucoma who undergo cataract surgery with implantation of the Alcon Vivity Extended Range Intraocular Lens (IOL).

NCT ID: NCT04670406 Completed - Clinical trials for Spinal Cord Injuries

A Guided Online ACT Intervention Combined With Psychoeducation for People With Spinal Cord Injury

Start date: May 7, 2021
Phase: N/A
Study type: Interventional

The purpose of this preliminary study is to examine the effects of a guided online acceptance and commitment therapy (ACT) intervention combined with psychoeducation on people with spinal cord injury (SCI) who experience psychological distress.

NCT ID: NCT04669899 Completed - Cancer Clinical Trials

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

Start date: January 12, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

JTX-8064-101 is a Phase 1/2, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose (RP2D) of JTX-8064 alone and in combination with a PD-1 inhibitor (PD-1i).

NCT ID: NCT04669808 Completed - Clinical trials for Basal Cell Carcinoma

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma

Start date: December 28, 2020
Phase: Phase 2
Study type: Interventional

This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with Basal Cell Carcinoma (BCC). Goals: - To determine the safe and effective recommended dose of STP705 for the treatment of basal cell carcinoma. - Analysis of biomarkers common to BCC formation pathway including TGF-β1 and COX-2.

NCT ID: NCT04669665 Completed - Clinical trials for Depressive Disorder, Major

A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

Start date: December 17, 2020
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy, safety, and tolerability of SLS-002 (intranasal racemic ketamine) in addition to standard of care on symptoms of Major Depressive Disorder (MDD) and suicidality, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.

NCT ID: NCT04669600 Completed - Clinical trials for Immune Thrombocytopenia (ITP)

A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

Start date: February 4, 2021
Phase: Phase 2
Study type: Interventional

Primary Objective: - To evaluate the effect of BIVV020 on the durability of platelet response in participants with persistent/chronic immune thrombocytopenia (ITP) Secondary Objectives: - To assess the safety and tolerability of BIVV020 - To assess the pharmacokinetics of BIVV020 - To assess the response rate of treatment with BIVV020 - To assess the time to response - To assess the effect of treatment with BIVV020 on the requirement for rescue ITP therapy - To assess the immunogenicity of BIVV020

NCT ID: NCT04669561 Completed - Dry Eye Clinical Trials

The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study

CLEAR
Start date: March 17, 2021
Phase: Phase 4
Study type: Interventional

In patients with dry eye, defined as corneal staining and a reduced tear breakup time, lifitegrast will improve higher order aberrations, ocular scatter index, corneal staining, and TBUT as soon as 1 week after initiating treatment.

NCT ID: NCT04669301 Completed - Clinical trials for Cognitive Impairment

Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II

Start date: April 2, 2021
Phase: N/A
Study type: Interventional

Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively affect their functional independence and quality of life. Memory and Attention Adaptation Training (MAAT) is a promising treatment for CRCD that improves perceived cognition in younger cancer survivors, but needs to be adapted for older adults to address their unique needs. The proposed study will adapt MAAT for older adults using feedback from key stakeholders (older adults with cancer and their caregivers), and subsequently test the ability of MAAT to improve or maintain cognition for older adults with breast cancer receiving adjuvant chemotherapy.

NCT ID: NCT04669249 Completed - Opioid Use Disorder Clinical Trials

Reward-Based Recovery Outcomes Management for Opioid Use Disorder

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

A randomized pilot study assessing feasibility, acceptability, and preliminary effectiveness of a reward-based recovery management platform (PROCare) designed to enhance participation in outcomes monitoring, engagement in treatment care, and adherence to medication for opioid use disorder.